Gritstone bio, Inc.
GRTS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.53 | -0.09 | 0.21 | -0.64 |
| FCF Yield | -53.56% | -38.84% | -5.53% | -62.20% |
| EV / EBITDA | -2.17 | -2.67 | -13.79 | -0.04 |
| Quality | ||||
| ROIC | -99.20% | -52.57% | -29.66% | -51.04% |
| Gross Margin | -470.32% | -69.28% | 69.18% | -2,095.76% |
| Cash Conversion Ratio | 0.88 | 0.97 | 0.67 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -69.46% | 31.92% | 120.38% | 50.38% |
| Free Cash Flow Growth | -3.61% | -116.99% | 39.38% | 8.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | 0.14 | 0.97 | 1.47 |
| Interest Coverage | -38.31 | -97.51 | -2,032.68 | -8,834.75 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 4.74 | 0.92 | 0.00 |
| Cash Conversion Cycle | -120.28 | -99.02 | 309.89 | -39.44 |